Vaccination against the type III secretion system of P. aeruginosa is a potential prophylactic strategy for reducing the incidence and improving the poor prognosis of P. aeruginosa pneumonia. In this study, the efficacies of three different adjuvants, Freund's adjuvant (FA), aluminum hydroxide (alum) and CpG oligodeoxynucleotide (ODN), were examined from the viewpoint of inducing PcrV-specific immunity against virulent P. aeruginosa. Mice that had been immunized intraperitoneally with recombinant PcrV formulated with one of the above adjuvants were challenged intratracheally with a lethal dose of P. aeruginosa. The PcrV-FA immunized group attained a survival rate of 91%, whereas the survival rates of the PcrV-alum and PcrV-CpG groups were 73% and 64%, respectively. In terms of hypothermia recovery after bacterial instillation, PcrV-alum was the most protective, followed by PcrV-FA and PcrV-CpG. The lung edema index was lower in the PcrV-CpG vaccination group than in the other groups. PcrV-alum immunization was associated with the greatest decrease in myeloperoxidase in infected lungs, and also decreased the number of lung bacteria to a similar number as in the PcrV-FA group. There was less neutrophil recruitment in the lungs of mice vaccinated with PcrV-alum or PcrV-CpG than in those of mice vaccinated with PcrV-FA or PcrV alone. Overall, in terms of mouse survival the PcrV-CpG vaccine, which could be a relatively safe nextgeneration vaccine, showed a comparable effect to the PcrV-alum vaccine.
Despite much research effort being directed at vaccine development against infections caused by P. aeruginosa, no licensed vaccine for preventing infections with this pathogen is clinically available (7) (8) (9) (10) . One probable explanation for such a vaccine not having been developed is the multiple virulence mechanisms of P. aeruginosa, which include secretion of various toxic exoproducts such as exotoxin A, exoenzymes, elastases, alkaline protease, phospholipase C and pyocyanins (11) (12) (13) (14) . In addition, the structural components of P. aeruginosa, which include lipopolysaccharides, flagella and outer membrane proteins, are also associated with variations in its virulence profile. The above factors have all been investigated as potential vaccine targets in their own right (15) (16) (17) (18) (19) (20) .
Some of the many trials in this area have failed, whereas others are still on the long road to clinical trials (8) . Our trial, which is based on targeting the TTSS of P. aeruginosa, is one of the on-going experimental trials (13, 21, 22) . TTSS, a major virulence mechanism found in various major gramnegative species, has a highly homologous genetic organization. Through TTSS, bacteria can directly translocate their toxins into the cytosol of the targeted eukaryotic cells to hijack intracellular signaling (23, 24) . In the case of P. aeruginosa, four type III secretory toxins, ExoS, ExoT, ExoU and ExoY have been identified (13, 14) . We have been focusing on the TTSS because the fatal pathogenesis of P. aeruginosa infection is frequently associated with development of septic shock and multiple organ failure and certain strains of P. aeruginosa can cause necrosis of the lung epithelium and disseminate into the circulation, this process being dependent on the TTSS (21) . In short, the type III secretory translocation of ExoU, which has been identified as a major cytotoxin with phospholipase A 2 activity, induces death in lung epithelial cells and alveolar macrophages, which eventually causes bacteremia, sepsis and death (25) (26) (27) . Therefore, blocking ExoU translocation has great potential to reduce the lethality of P. aeruginosa pneumonia. With the aim of impeding toxin translocation through the TTSS, we previously identified the molecular target PcrV, which is the cap structure of an injection needle in the type III secretion apparatus (21, 22) . PcrV is present in most P. aeruginosa strains that cause acute infections, especially in the ones associated with poor clinical outcomes (28) . Furthermore, the PcrV's structure is conserved among strains and is not associated with antibiotic resistance (28) . These characteristics of PcrV, along with its role in the translocation of type III secretory toxins, have made it a more promising antigen for a P. aeruginosa vaccine than the many other antigen candidates in this species. Encouragingly, vaccination with recombinant PcrV has been shown to reduce the mortality in normal and immunocompromised mice infected with a lethal dose of virulent P. aeruginosa (29, 30) , whereas passive immunization with anti-PcrV IgG is reportedly protective against the pathogen in various animal models (31) (32) (33) (34) (35) (36) (37) . Commercially available immunoglobulin solutions containing anti-PcrV antibodies and immunoglobulin derived from high anti-PcrV titer sera also have prophylactic effects on P. aeruginosa pneumonia in a mouse model (38) (39) (40) .
Freund's adjuvant, named after Jules T. Freund, is a water-in-oil emulsion prepared from non-metabolizable oils. The complete form contains inactivated and dried mycobacteria, whereas the incomplete form lacks these mycobacterial components. It has been used as an adjuvant for stimulating potent, specific adaptive immune responses in many experimental animal models of vaccination (41) . However, its clinical use is forbidden because it can cause arthritis, skin ulceration and necrosis. Development of an effective vaccine against P. aeruginosa requires making an appropriate choice from the clinically applicable adjuvants available. In this study, with the aim of developing a PcrV vaccine for preventing lethal P. aeruginosa pneumonia, we examined the efficacy of three adjuvants, FA, alum and CpG ODN in PcrV vaccination experiments using a mouse model of P. aeruginosa pneumonia.
MATERIALS AND METHODS

Recombinant PcrV and adjuvants
Endotoxin-free rePcrV was prepared as reported previously (38) . Briefly, the PcrV coding sequence was PCR amplified from the P. aeruginosa PAO1 chromosome. The PCR fragments were ligated into an Escherichia coli expression vector (pQE30, Qiagen, Hilden, Germany) to create a protein construct with a six tandem histidine residue (His-tag) at the aminoterminal. The expression vector was introduced into E. coli strain M15 (Qiagen) and recombinant proteins produced from culture of that E. coli strain via isopropylthio-b-galactoside induction. Proteins in the crude extract were purified with nickel-nitrilotriacetic acid agarose columns (Novex R901-15, Thermo Fisher Scientific, Waltham, MA, USA), dialyzed for 72 hr against PBS (P3813; Sigma-Aldrich, St. Louis, MO, USA) and then applied to endotoxin removal resin columns (Pierce, Thermo Fisher Scientific, Rockford, IL, USA). The purity of rePcrV was evaluated using Vaccines against P. aeruginosa pneumonia in which an intense single band appears on the Coomassie blue-stained gel.
Complete and incomplete Freund's adjuvants (FCA and FIA, respectively) were purchased from SigmaAldrich. Aluminum hydroxide gel (alum, 20 mg/mL) was purchased from Wako Pure Chemical Industries (Osaka, Japan). The K type of CpG ODN (K3) (5 0 -ATCGACTCTCGAGCGTTCTC-3 0 ) was synthesized by GeneDesign (Ibaraki, Japan) (42) , and the resultant solid CpG ODN dissolved in saline at a concentration of 1 mg/mL.
Immunizations
Certified pathogen-free male ICR mice (4 weeks old) were purchased from Shimizu Laboratory Supplies (Kyoto, Japan). The mice were housed in cages under pathogen-free conditions. The protocols for all animal experiments were approved by the Animal Research Committee of Kyoto Prefectural University of Medicine, Kyoto, Japan prior to starting the experiments.
rePcrV (10 mg/dose) was formulated alone or in combination with one of the following adjuvants: FCA/ FIA (100 mL/dose), alum (100 mL/dose) or CpG ODN (10 mg/dose) ( Table 1) . Each solution provided a 200 mL dose with saline. rePcrV and FCA/FIA were conjugated sufficiently enough to create an emulsion just before the immunizations were administered. rePcrV and alum were mixed the day before immunization and gently rotated overnight to assist conjugation. On Day 0, four groups of mice were immunized i.p. with one of the following vaccines: PcrV-FA (FA denotes FCA/FIA), PcrV-alum, PcrV-CpG or PcrV alone. Additionally, two groups of mice were injected with alum (100 mL/dose) alone or CpG ODN (10 mg/dose) alone, and the other two groups with saline alone (Fig. 1) . On Days 20 and 40 post-immunization, the same vaccine formulations were given as booster immunizations or injections, except for in the PcrV-FA group, in which FCA was used for the first immunization and FIA for the second and third ones.
Anti-PcrV titer measurements
On Day 60 (20 days after the final immunization), peripheral blood from the immunized mice was collected and diluted 1:1000 with saline. To determine mouse antibody responses to the vaccines, PcrV-specific IgG titers were measured with an ELISA. rePcrV was diluted to a concentration of 1 mg/mL with coating buffer (0.1 mM NaHCO 3 , pH 8.2). Microtiter plates (Nunc C96 Maxisorp, Thermo Fisher Scientific) were coated with 50 mL per well of the diluted antigen and then incubated at 4°C overnight. The plates were washed twice with PBS/T (Wako Pure Chemical Industries) and then blocked with 200 mL per well of PBS containing 1% BSA at 4°C overnight. After washing twice with PBS/T, 100 mL per well of the serum samples was added to each well and the plates incubated at 4°C overnight. The plates were then washed four times and 100 mL per well of goat anti-mouse IgG (whole molecule)-peroxidase antibody (A8924; Sigma-Aldrich) diluted 1: 20,000 was then added to detect the attached IgG antibodies. After incubation at 37°C for 2 hr, the plates were washed six times and 200 mL per well of 3,3 0 ,5,5 0 -tetramethylbenzidine liquid substrate system for ELISA (T0440; SigmaAldrich) added to visualize the antibody complexes. The plates were incubated at room temperature for 30 min before the reaction was stopped by 100 mL per well of 0.5 M sulfuric acid, after which the OD at 450 nm was measured by a microplate reader (MTP-880Lab; Corona Electric, Ibaraki, Japan).
Immunoglobulin isotyping ELISA
In addition to total IgG titers, the PcrV-specific antibody isotypes activated by the vaccines were also evaluated. The microtiter plates were coated and blocked and serum samples added the same as for the total IgG titer measurements. After washing the plates, which had previously been incubated with the serum samples, 100 mL per well of goat anti-mouse Mouse Monoclonal Antibody Isotyping Reagent (ISO2; Sigma-Aldrich), specific for each of IgG 1 , IgG 2a , IgG 2b , IgG 3 and IgA, was diluted 1: 1000 and then added. After incubation at room temperature for 30 min and washing four times with PBS/T, 100 mL per well of rabbit anti-goat IgG (whole molecule)-peroxidase antibody (A5420, Sigma-Aldrich) diluted 1: 20,000 was added. The plates were incubated at room temperature for 15 min and washed six times with PBS/T, after which the antibody complexes were visualized as described above.
Infectious challenge with P. aeruginosa
The P. aeruginosa PA103 strain, which was isolated originally from a patient in Australia in the late 1960s, was used in the challenge experiments (20) . This strain has a cytotoxic phenotype with positive type III secretion of ExoT and ExoU, the TTSS genotype exoS -, exoT þ , exoU þ and exoY þ and an ExoY secretion-negative phenotype caused by a codon mutation. Bacterial suspensions were prepared as described previously (27, 43) . Cultures were grown at 32°C for 12 hr in a shaking incubator and then centrifuged at 3000 g for 10 min. The bacterial pellets were washed three times in saline and diluted to the appropriate number of CFU/mL, as determined by spectrophotometry. The bacterial count was confirmed by determining the CFU from a diluted aliquot on a sheep blood agar plate. On Day 65 (25 days after the final immunization), the immunized mice were lightly anesthetized and infected intratracheally with PA103 (1.5 Â 10 6 CFU in 60 mL of saline), which was instilled into the left lung of each mouse through an endotracheal needle, as described previously (44, 45) . Mice in the saline-treated uninfected group, which had been injected with saline without the PcrV antigen, were not infected with PA103 and only given saline intratracheally. The survival and body temperatures of all mice were monitored over 24 hr, after which the surviving mice were euthanized and the lungs and blood collected from each mouse. The lungs were then homogenized using a homogenizer (Polytron PT10/35; Kinematica, Luzern, Switzerland) for further evaluation.
Bacteriological assay
Sequentially diluted solutions of lung homogenate or blood were inoculated on sheep blood agar plates and incubated at 37°C overnight. The CFU counts on the plates were used to determine the number of bacteria in 100 mL of undiluted lung homogenate or blood.
Lung edema index and myeloperoxidase assay
The lung edema index was obtained by measuring the wet-to-dry weight ratio of the lungs at 24 hr, as described previously (38) . MPO activity in the lung homogenates was measured as follows. The homogenates were centrifuged at 10,000 g at 4°C for 15 min. After removing the supernatant, KH 2 PO 4 (working solution buffered to pH 6.0) and 50 mM of hexadecyltrimethylammonium bromide (Sigma-Aldrich) were added to the precipitate. The mixture was processed by repeated sonication and freeze-thawing cycles, centrifuged under the conditions described above and the supernatant was collected. Aliquots (290 mL per well) of KH 2 PO 4 working buffer containing 0.167 mg/mL of 3,3'-dimethoxybenzidine dihydrochloride (Wako Pure Chemical Industries) and 0.001% H 2 O 2 were added to the microtiter plates and 10 mL per well of the supernatant samples (diluted 1:4) added to each well. After incubation at room temperature for 2 min, the OD at 450 nm was measured.
Histopathological assay
At 24 hr post-infection, a designated mouse from each group was sacrificed for histological analysis. The lungs were perfused with a 10% formalin neutral-buffered solution for fixation and then embedded in paraffin and the mounted sections stained with hematoxylin-eosin.
Statistical analysis
The Kaplan-Meier estimator and a log-rank test (Prism; GraphPad Software, La Jolla, CA, USA) were used to assess mouse survival. One-way anova and Bonferroni test (Instat; GraphPad Software) were used to compare total anti-PcrV IgG titers, antibody isotype titers, body temperatures, lung edema indexes and MPO activities. The Kruskal-Wallis non-parametric and Dunn's multiple comparison tests were used for comparing the bacterial numbers in the lungs. P < 0.05 was considered to denote statistical significance.
RESULTS
Immune responses induced by PcrV vaccines
To determine the adjuvant effects of alum and CpG ODN and compare them with that of FA, eight groups of mice were tested (Table 1) . Three groups of mice, PcrV-FA, PcrV-alum and PcrV-CpG, were immunized i.p. with PcrV vaccine formulated with either one of the adjuvants. One group of mice was immunized with PcrV alone and other two with saline as negative control groups. To evaluate the effect of the adjuvant alone, one mouse group was injected with alum and the other with CpG ODN; both of these treatments lacked the PcrV antigen. On Day 60, after the third immunization on Day 40, all four vaccinated groups, PcrV-FA, PcrV-alum, PcrV-CpG and PcrV alone, had significantly higher anti-PcrV titers than did the saline-treated group (P < 0.01 vs. saline-treated) (Fig. 2) . Mice in the PcrV-FA, PcrV-alum and PcrV-CpG groups had significantly greater anti-PcrV titers than did those in the PcrV alone group (P < 0.05 vs. PcrV alone). Among the three groups vaccinated with PcrV-FA, PcrV-alum, or PcrV-CpG, the anti-PcrV titers were the highest in the PcrV-FA group (P < 0.05 PcrV-FA vs. PcrV-alum).
Administration of alum alone or CpG alone did not result in increased anti-PcrV titers.
The isotypes of the PcrV-specific antibodies in the sera of the vaccinated mice were also measured (Fig. 3) . Of note, the immunoglobulin isotype distribution induced following vaccination could be an indicator of the type of protective immunity activated by the vaccine and/or adjuvant. PcrV-specific antibody isotypes did not increase in the groups immunized with alum alone or with CpG alone. Immunization with PcrV alone resulted in significantly greater anti-PcrV IgG 1 titers than in the saline-treated group (P < 0.001 vs saline-treated). Addition of FA, alum or CpG ODN to PcrV resulted in significantly greater anti-PcrV IgG 1 titers than with PcrV alone (P < 0.001 vs. PcrV alone); however, there were no statistically significant differences in IgG 1 titers between the PcrV-FA, PcrV-alum and PcrV-CpG groups. Combining PcrV with FA or with CpG ODN resulted in significantly greater anti-PcrV IgG 2a and IgG 2b titers than with PcrV alone and PcrV-alum (P < 0.001 vs. PcrV alone, P < 0.05 PcrV-FA and PcrVCpG vs. PcrV-alum). The anti-PcrV IgA titers in the PcrV-FA group were the highest among all the groups (P < 0.001 vs. PcrV alone, P < 0.05 PcrV-FA vs. PcrValum).
Protective immunity against bacterial challenge conferred by PcrV vaccines
Survival rate
On Day 65 after the first vaccine dose, all mouse groups except the saline-treated uninfected group were infected intratracheally with a lethal dose of P. aeruginosa PA103 strain and were then monitored for 24 hr. The survival rates were significantly greater in the PcrV-FA, PcrValum and PcrV-CpG groups than in the saline-treated infected group (P < 0.01 vs. saline-treated infected), whereas immunization with PcrV alone, alum alone or CpG alone did not improve their survival (Fig. 4  upper) . The PcrV-FA group had a significantly greater survival rate than the PcrV alone group (P < 0.05 vs. PcrV alone). All the infected mice became hypothermic 4 hr after the infection. Some of them recovered and survived, whereas others died or remained hypothermic (Fig. 4, lower panel) . The PcrV-FA, PcrV-alum, PcrVCpG and PcrV alone groups all had significantly higher body temperatures than the saline-treated infected group at 12 hr post-infection (P < 0.001 vs. saline-treated infected). Among the three groups vaccinated with PcrV-FA, PcrV-alum or PcrV-CpG, the PcrV-alum group made the best recovery from hypothermia at 24 hr post-infection (P < 0.05 PcrV-FA and PcrV-CpG vs. PcrV-alum); however, the difference in survival rates between the three groups was not statistically significant (Fig. 4, upper panel) .
Lung edema index
The lung edema index, which was used here to determine the severity of lung edema, was 3.3 AE 0.2 in the salinetreated uninfected group (Fig. 5, upper panel) . At 24 hr post-infection, the index was 5.5 AE 0.3 in the salinetreated infected group, 5.5 AE 0.2 in the alum alone group and 5.2 AE 0.4 in the CpG alone group. Immunization with PcrV-FA or PcrV-CpG resulted in significantly less severe lung edema than in the saline-treated infected group, the lowest index being recorded for the PcrVCpG group (4.5 AE 0.5) (P < 0.05 vs. saline-treated infected); however, there was no statistically significant difference in the severity of lung edema between the three groups vaccinated with PcrV-FA, PcrV-alum or PcrV-CpG.
MPO activity
To evaluate the severity of inflammation in the P. aeruginosa-infected lungs, the MPO activities of the lung homogenates at 24 hr post-infection were measured ( Fig. 5, lower panel) . Significantly lower activities were found in the lungs of the PcrV-FA, PcrV-alum, PcrVCpG and PcrV alone groups than in those of the salinetreated infected group (P < 0.001 vs. saline-treated infected). Among the three groups vaccinated with PcrV-FA, PcrV-alum, or PcrV-CpG, the PcrV-FA group showed the highest MPO activity (P < 0.05 PcrV-FA vs. PcrV-alum).
Bacteriological evaluation
The numbers of bacteria in the lungs of all mice and in the blood of those surviving at 24 hr post-infection were measured (Fig. 6 ). The medians (first quartile) bacterial counts in the lungs of the PcrV-FA and PcrV-alum groups were 2.6 Â 10 4 (1.5 Â 10 4 ) CFU and 5.6 Â 10 4 (9.1 Â 10 3 ) CFU, respectively, both of which were significantly lower than that of the saline-treated infected group (median 6.6 Â 10 7 ; first quartile 1.0 Â 10 7 CFU; P < 0.05 vs. saline-treated infected). The PcrV-CpG group had a lower bacterial count, 4.5 Â 10 6 (1.3 Â 10 5 ) CFU than the PcrV alone (median 6.3 Â 10 6 ; first quartile 3.3 Â 10 5 CFU) and saline-treated infected groups; however, these differences were not statistically significant. There were also no statistically significant differences between the other infected groups and the PcrV alone or PcrV-alum groups. Bacteremia was detected in only four of the surviving mice (one from each of the PcrV-FA, PcrV-CpG, alum alone and CpG alone groups).
Lung histology
Post-infection histological changes in the mouse lungs were evaluated (Fig. 7) . Increased neutrophil infiltration, alveolar hemorrhage and destruction of the alveolar structure in the lungs of the PcrV-FA, PcrV alone and saline-treated infected groups were observed. These inflammatory changes in the lungs were less severe in the PcrV-CpG group and even more so in the PcrV-alum group. No inflammatory changes were observed in the lungs of the saline-treated uninfected group. The PcrV-alum and PcrV-CpG against PcrV-FA, PcrV alone and saline-treated infected groups were evaluated according to scores for the experimental variables (Table 2 ; Fig. 8 ). The effects of CpG ODN were generally similar to those of alum, indicating that it would likely be a relatively safe vaccine component of next-generation vaccines.
DISCUSSION
In this study, we compared the efficacy of three different adjuvants, Freund's adjuvant, alum and CpG ODN, in inducing specific immunity against P. aeruginosa PcrV. The results clearly show that, with PcrV as the vaccine antigen, all three adjuvants tested, FA, alum and CpG ODN, were effective in inducing protective immunity against infection with P. aeruginosa. Previous studies have shown that alum mainly induces Th2 type immune responses (46) , whereas CpG ODN generally induces Th1 type immune responses (47, 48) . As for the PcrValum group, in this study there was a marked increase in anti-PcrV IgG 1 titers but a smaller increase in IgG 2a titers, which indicates Th2-biased immune responses. In contrast, there was a greater increase in anti-PcrV IgG 2a titers and an increase in IgG 1 titers in the PcrV-CpG group, indicating induction of Th1 type immune responses and more balanced immune activity.
It has not yet been determined what type of immune responses are needed to provide or enhance effective protective immunity against P. aeruginosa infections and their various clinical manifestations (7) . Although translocation inhibition of type III secretory toxins by anti-PcrV antibodies has been suggested to be the main mechanism of the PcrV vaccine, activation of cellular immunity by CpG ODN could be helpful against P. aeruginosa. Previous studies have shown the effectiveness of CpG ODN as an adjuvant in a P. aeruginosa vaccine consisting of O-polysaccharide from serotype IATS-1 coupled with Toxin A (49), and in a DNA vaccine containing genes encoding Exotoxin A and PcrV (50) . Moreover, in a Yersinia pestis vaccine study, a multiple antigen peptide synthesized from LcrV, a V antigen with homology to PcrV, was shown to be highly effective when combined with CpG ODN (51). Our study is the first to demonstrate the efficacy of CpG ODN as an adjuvant for a single PcrV antigen in a P. aeruginosa vaccine. Aluminum compounds such as aluminum hydroxide, Al(OH) 3 , and aluminum phosphate, AlPO 4 , typically referred to as "alum", are adjuvants that have been licensed by the US Food and Drug Administration. Both of these adjuvants have been widely used in numerous human vaccines for almost a century, including vaccines against diphtheria-tetanus-pertussis, human papillomavirus and hepatitis B virus. Alum's mechanism of action has been researched over many years but is still not fully understood. It has been shown that alum enhances antigen uptake by antigen presenting cells, increases cell recruitment to the injection site and stimulates immune cells (52, 53) . Recent studies have shown that alum's immunostimulatory effects are related to activation of the NLRP3 inflammasome and Syk-PI3 kinase pathways and that alum stimulates the release of uric acid and host DNA, both of which act as endogenous danger signals, by inducing cell necrosis (53) (54) (55) . Alum induces strong Th2 type humoral immune responses primarily mediated by secreted antigen-specific antibodies (56) , but, by contrast, is a poor inducer of cellular immune responses.
CpG ODN is a short, single-stranded synthetic DNA fragment containing an unmethylated CpG sequence (CpG motif). The sequence is relatively common in the genomes of most bacteria and DNA viruses; however, these sequences are suppressed and methylated in vertebrate genomes (32, 34) . By interacting with TLR 9, CpG ODN activates plasmacytoid dendritic cells and B cells, produces inflammatory cytokines and secondarily activates NK cells, monocytes and neutrophils, leading to promotion of Th1 type humoral and cellular immune responses (57) . Because of its immunostimulatory effects, CpG ODN has been used in various immunotherapies against infectious diseases, cancer, asthma and other allergies. Numerous vaccines containing CpG ODN have been developed and some of them have progressed to clinical trials in humans (57, 58) .
There would be a variety of candidates receiving a P. aeruginosa vaccine, including critically ill patients, immunocompromised patients, patients with cystic fibrosis or other diseases that impair respiratory tract defenses, preoperative patients scheduled for major surgery and workers who are at risk of burns or combatrelated wound infections (10) . Also because, according to a population-based study of P. aeruginosa bloodstream infections in Canada (59), people aged over 60 years tend to have an higher risk of P. aeruginosa infections, it may be reasonable and cost-effective to target everyone over this age with a P. aeruginosa vaccine to reduce their high risk of hospitalization and nosocomial infections. The data in our study do not necessarily assure similar results in human clinical trials; nevertheless, in this study, CpG ODN appeared comparable to alum. Further optimization of the dose and vaccination frequency, obtaining the ideal ratio of antigen to adjuvant, and the best administration route, will be the next step to achieve clinical application in humans. 
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